Listed by the USPTO as KONOPKA, CATHERINE ANNE
Tech Center 4100 • Art Units: 1600 1611 1613 1632 1635 1636 1638 1642 1796 4100
This examiner grants 58% of resolved cases
KONOPKA, CATHERINE ANNE works in tech center 4100 and art unit 1600. Her profile records 212 resolved cases, an allowance rate of 57.5%, and a median of 1387 days to allowance. The allowance rate shows that allowance occurred in a majority of resolved matters, while the median indicates a lengthy prosecution period.
The interview lift is 66.2%, demonstrating a strong positive association between interviews and allowance in the measured record. Practitioners may give interviews a central role in planning, while documenting any resulting claim strategy in the written response. The listed companies are University of Florida Research Foundation Inc., The Brigham and Women's Hospital Inc., and University of Massachusetts. The associated firms are WOLF GREENFIELD & SACKS, P.C., Casimir Jones, S.C., and HOWSON & HOWSON LLP.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18267144 | METHOD FOR PROGRAMMABLE CONTROL OF RNA TRANSCRIPT LEVELS WITH AUTOREGULATED CRISPR-CAS13D | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18045873 | AAV VARIANTS WITH HOST ANTIBODY ESCAPE CAPABILITIES AND ALTERED TISSUE TARGETING PROPERTIES | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18659831 | PHARMACEUTICAL COMBINATIONS FOR TREATMENT OF HBV | Non-Final OA | Hoffmann-La Roche Inc. |
| 18553357 | Specific Oligonucleotide-Programmed Readthrough of Nonsense Codons | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 18213505 | MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 18473498 | TREATMENT AND DETECTION METHODS FOR INFLAMMATORY BOWEL DISEASE | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 18394385 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | Non-Final OA | EDITAS MEDICINE, INC. |
| 18048238 | DISCOVERY AND ENGINEERING OF INTEGRASES FOR HIGH-EFFICIENCY GENE INTEGRATION | Non-Final OA | Massachusetts Institute of Technology |
| 18712524 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Non-Final OA | Ohio State Innovation Foundation |
| 18014692 | USE OF SATIVENE, AND RECOMBINANT BIOCONTROL FUNGUS AND MUSCARDINE CADAVER AND USE THEREOF | Non-Final OA | ZHEJIANG UNIVERSITY |
| 18571967 | COMPOSITIONS AND METHODS FOR IMPROVED PROTEIN TRANSLATION FROM RECOMBINANT CIRCULAR RNAS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17596186 | SYSTEM AND METHOD FOR COMBATING MYCOBACTERIUM TUBERCULOSIS INFECTIONS | Final Rejection | Tata Consultancy Services Limited |
| 18798198 | Treatment Of Hyperglycemia With Solute Carrier Family 39 Member 5 (SLC39A5) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17823726 | HOST DEFENSE SUPPRESSING METHODS AND COMPOSITIONS FOR MODULATING A GENOME | Final Rejection | FLAGSHIP PIONEERING INNOVATIONS VI, LLC |
| 18535658 | SYNTHETIC IMMUNOMODULATION WITH A CRISPR SUPER-REPRESSOR IN VIVO | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 17756078 | LARGE-SCALE COMBINED CAR TRANSDUCTION AND CRISPR GENE EDITING OF T CELLS | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18506637 | COMPOSITIONS AND METHODS OF USE FOR MUTATED HOTAIR IN THE TREATMENT OF CANCERS | Non-Final OA | The Regents of the University of Colorado, a body corporate |
| 16174759 | MANUFACTURING METHOD OF NANODISC COMPRISING AN OLFACTORY RECEPTOR PROTEIN AND NANODISC COMPRISING AN OLFACTORY RECEPTOR PROTEIN MANUFACTURED BY THE SAME | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18257504 | CHEMICALLY MODIFIED CRISPR-CAS13 GUIDE RNAS | Final Rejection | New York University |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy57.5% of resolved applications examined by Catherine Anne Konopka were allowed (212 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +66.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Catherine Anne Konopka took 1,387 days on average from filing to allowance.
Catherine Anne Konopka examines applications in Art Unit 1600 in Tech Center 4100.
